Skip to main content
Rajat Bannerji, MD, Oncology, New Brunswick, NJ, Robert Wood Johnson University Hospital

RajatBannerjiMDPhD

Oncology New Brunswick, NJ

Hematologic Oncology

Associate Professor, Medicine, UMDNJ-Robert Wood Johnson Medical School

Dr. Bannerji is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Bannerji's full profile

Already have an account?

  • Office

    195 Little Albany Street
    East Tower 9th fl. Room 993
    New Brunswick, NJ 08901
    Phone(732) 235-4687
    Fax(732) 448-7894
  • Is this information wrong?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1995 - 1998
  • Weill Cornell Medical College of Cornell University
    Weill Cornell Medical College of Cornell UniversityClass of 1995

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2006 - 2008
  • NJ State Medical License
    NJ State Medical License 2006 - 2023
  • PA State Medical License
    PA State Medical License 1998 - 2008
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
    Rajat Bannerji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
    Rajat Bannerji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
    Rajat Bannerji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • REGN1979 Shows Good Activity in Pretreated Aggressive B-NHL
    REGN1979 Shows Good Activity in Pretreated Aggressive B-NHLJanuary 15th, 2020
  • Exploring Clinical Activity of an Immunotherapy Drug That Targets Lymphomas
    Exploring Clinical Activity of an Immunotherapy Drug That Targets LymphomasNovember 29th, 2018
  • FDA Pushes Pause on 2 Regeneron Lymphoma Trials for Cytokine Release Syndrome
    FDA Pushes Pause on 2 Regeneron Lymphoma Trials for Cytokine Release SyndromeDecember 16th, 2020
  • Join now to see all

Professional Memberships

Hospital Affiliations